PUTEAUX, France, March 27, 2024--(BUSINESS WIRE)--Regulatory News: ORPEA S.A. (ISIN FR001400NLM4) (Paris:ORP) and Natixis ODDO BHF signed, on 26 March 2024, amendment no. 2 to the liquidity and market surveillance contract entered into on 30 November 2022, relating to its ordinary shares admitted to trading on Euronext Paris, in accordance with the Autorité des Marchés Financiers (AMF)’s decision no. 2021-01 dated 22 June 2021 related to the establishing of liquidity contracts on shares as accepted market practice. Also within the limits of the AMF’s decision no. 2021-01 dated 22 June 2021, ORPEA S.A. decided to increase the resources allocated to the liquidity contract by €1,000,000. The position after contribution of these new resources on 26 March 2024 is: - 46 shares, - 1,415,570.95 €. About emeis With 76,000 experts and professionals in healthcare, care, and supporting the most vulnerable among us, emeis operates in 20 countries with five core activities: psychiatric clinics, medical care and rehabilitation clinics, nursing homes, home care services, and assisted-living facilities. Every year, emeis welcomes 267,000 residents, patients, and other beneficiaries. emeis is committed and taking action to rise to a major challenge facing our civilisation, i.e. the increase in the number of people put in a vulnerable position as a result of accidents, old age, or the rising number of cases of mental illness. ORPEA S.A., the Group's parent company is 50.2 % owned by Caisse des Dépôts, CNP Assurances, MAIF, and MACSF Epargne Retraite. It is listed on the Euronext Paris stock exchange (ISIN: FR001400NLM4) and a member of the SBF 120 and CAC Mid 60 indices. Website: www.emeis.com View source version on businesswire.com: https://www.businesswire.com/news/home/20240327743090/en/ Contacts Press Contacts Isabelle Herrier Naufle Medias & e-reputation Director 07 70 29 53 74 [email protected] IMAGE 7 Charlotte LE BARBIER // Laurence HEILBRONN 06 78 37 27 60 // 06 89 87 61 37 [email protected] // [email protected] Investor Relations Benoit LESIEUR Investor Relations Director [email protected] Toll-free number for shareholders: 0 805 480 480 NEWCAP Dusan ORESANSKY 01 44 71 94 94 [email protected]
ORPEA S.A.: Increase of the Resources Allocated to the Liquidity Contract Entered With Natixis ODDO BHF
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...